Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
Important catalysts expected to occur during the fourth quarter of 2019 include US approval decisions for brolucizumab in wet age-related macular degeneration (AMD) and for a long-acting cabotegravir and rilpivirine combination, CARLA, to treat HIV-1 infection, as well as top-line results from a phase III study of SAGE-217 in major depressive disorder (MDD).